Pfizer has not completely exited or abandoned its corporate presence in Pakistan; rather, like several multinational pharmaceutical companies operating in the region, it has periodically restructured parts of its manufacturing, importing, and local distribution models. These strategic adjustments are typically driven by complex domestic regulatory frameworks, pricing disputes with government drug authorities over hard currency inflation, and shifting global manufacturing consolidation strategies.